CDC describes demographics of JYNNEOS vaccine recipients for monkeypox prevention in the US

A descriptive report from the Centers for Disease Control and Prevention (CDC) outlines the demographic characteristics of individuals who received the JYNNEOS vaccine for monkeypox prevention in the United States. The study type, sample size, and follow-up duration are not reported. The analysis focuses on the population receiving the vaccine rather than clinical outcomes.

No primary or secondary clinical outcomes, such as vaccine efficacy against monkeypox infection, are presented. The report does not include data on adverse events, serious adverse events, discontinuations, or tolerability. A comparator group was not reported.

Key limitations include the absence of clinical outcome data, an unspecified sample size, and no information on study design or funding. The practice relevance is not reported, as this is a demographic description rather than an efficacy or safety study. This report provides epidemiological context but offers no evidence regarding the vaccine's clinical effectiveness or safety profile in this population.